Although worldwide use of asbestos has decreased, the incidence of malignant pleural mesothelioma (MPM) is expected to increase over the next few decades. A number of scoring systems has been proposed to assess clinicopathologic features and to predict the prognosis. We assessed the relationship between patients’ features and disease evolution in order to choose the best treatment able to prolong overall survival (OS) and progression-free survival (PFS).
Methods
We retrospectively analyzed patients with locally advanced or metastatic MPM, treated at the Department of Medical Oncology, Università Politecnica Marche, Italy, from January 2003 to September 2013. Data on age, sex, smoking history, asbestos exposure, performance status, tumor stage, histology, type of treatment, and routine laboratory tests including complete blood count panel, date of death, or censored status were collected. The OS and PFS were estimated using Kaplan-Meier method and Cox analysis was performed to analyze the prognostic relevance of clinical parameters.
Results
We enrolled a total of 62 patients. Univariate analysis showed that histologic type, performance status, response to first-line therapy, pretreatment hemoglobin levels, and plasmatic Ca125 were significant prognostic factors. Conversely, no significant correlation was found between age, sex, smoking history, reported exposure to asbestos, stages at diagnosis, treatments, and OS and PFS.
Conclusions
Our results showed that anemia and increased Ca125 might be considered negative prognostic parameters in MPM patients and confirmed the prognostic role of histotype, performance status, and response to first-line chemotherapy.
DriscollTNelsonDISteenlandKThe global burden of disease due to occupational carcinogens. Am J Ind Med2005; 48 (6):419–431
2.
ParkEKTakahashiKHoshuyamaTGlobal magnitude of reported and unreported mesothelioma. Environ Health Perspect2011;119 (4):514–518
3.
MurayamaTTakahashiKNatoriYKurumataniNEstimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med2006; 49 (1):1–7
4.
MontanaroFBrayFGennaroVMerlerETyczynskiJEMaxwell ParkinDENCR Working Group. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control2003;14 (8):791–803
5.
TseLAYuITGogginsWAre current or future mesothelioma epidemics in Hong Kong the tragic legacy of uncontrolled use of asbestos in the past?Environ Health Perspect2010; 118 (3):382–386
6.
HodgsonJTMcElvennyDMDarntonAJPriceMJPetoJThe expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer2005;92 (3):587–593
van MeerbeeckJPScherpereelASurmontVFBaasPMalignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol2011;78 (2):92–111
9.
LuckrazHRahmanMPatelNSzafranekAGibbsARButchartEGThree decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg2010;37 (3):552–556
10.
VogelzangNJRusthovenJJSymanowskiJPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol2003;21 (14):2636–2644
11.
MontanaroFRosatoRGangemiMSurvival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer2009;124 (1):201–207
12.
EdwardsJGAbramsKRLevermentJNSpytTJWallerDAO’ByrneKJPrognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax2000;55 (9):731–735
13.
SteeleJPRuddRMMalignant mesothelioma: predictors of prognosis and clinical trials. Thorax2000;55 (9):725–726
14.
PassHIBiomarkers and prognostic factors for mesothelioma. Ann Cardiothorac Surg2012;1 (4):449–456
15.
GillRRRichardsWGYeapBYEpithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. AJR Am J Roentgenol2012;198 (2):359–363
16.
SharifSZahidIRoutledgeTScarciMDoes positron emission tomography offer prognostic information in malignant pleural mesothelioma?Interact Cardiovasc Thorac Surg2011;12 (5):806–811
RuschVWFrom the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest1995;108 (4):1122–1128
19.
CurranDSahmoudTTherassePvan MeerbeeckJPostmusPEGiacconeGPrognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol1998;16 (1):145–152
20.
HerndonJEGreenMRChahinianAPCorsonJMSuzukiYVogelzangNJFactors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest1998;113 (3):723–731
21.
SuzukiHHirashimaTKobayashiMPrognostic factors in malignant pleural mesothelioma: a retrospective study. Intern Med2012;51 (7):707–710
22.
NojiriSGembaKAoeKSurvival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol2011;41 (1):32–39
23.
TanrikuluACAbakayAKaplanMAA clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration2010;80 (6):480–487
24.
FrancartJVaesEHenrardSA prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer2009;45 (13):2304–2311
25.
KadotaKSuzukiKSimaCSRuschVWAdusumilliPSTravisWDPleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol2011;6 (5):896–904
26.
KadotaKKachalaSSNitadoriJHigh SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology. J Thorac Oncol2012;7 (7):1192–1197
27.
BalduyckBTrousseDNakasAMartin-UcarAEEdwardsJWallerDATherapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?Ann Thorac Surg2010;89 (3):907–911
28.
SugarbakerDJWolfASChirieacLRClinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg2011;40 (2):298–303
29.
KaoSCVardyJChatfieldMValidation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer2013; 14 (1):70–77
30.
SteeleJPPrognostic factors for mesothelioma. Hematol Oncol Clin North Am2005;19 (6):1041–1052
31.
WanSLaiYMyersREPost-diagnosis hemoglobin change associates with overall survival of multiple malignancies: results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers. BMC Cancer2013;10 (13):340
32.
KnightKWadeSBalducciLPrevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med2004;116(Suppl 7A):11S–26S
33.
TomitaMShimizuTHaraMAyabeTOnitsukaTPreoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. Anticancer Res2009; 29 (7):2687–2690
34.
BerardiRBrunelliATamburranoTPerioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer2005;49 (3):371–376
35.
BerardiRBraconiCMantelloGAnemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Ann Oncol2006;17 (11):1661–1664
CaroJJSalasMWardAGossGAnemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer2001;91 (12):2214–2221
38.
HoffCMHansenHSOvergaardMThe importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy: results from the randomized DAHANCA 5 study. Radiother Oncol2011;98 (1):28–33
39.
CreaneyJvan BruggenIHofMCombined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest2007;132 (4):1239–1246
40.
SchaubNPAlimchandaniMQuezadoMA novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol2013;20 (2):555–561
